Teva US approval for WELTRUZA, first only, once‑monthly subcutaneous long-acting schizophrenia injectible

Teva wins FDA approval for WELTRUZA, first and only once‑monthly subcutaneous long-acting injectable olanzapine for adult schizophrenia in U.S.

https://finviz.com/stock?t=TEVA&p=d